SOX2 and head and neck squamous cell carcinoma: Finally, in clinical practice, unresectable advanced HNSCC patients are seldom treated with a solitary therapeutic approach, with most regimens incorporating a combination of radiotherapy, immunotherapy, or chemotherapy.[3] While our T‐sgSOX2‐cLNPs demonstrated a significant therapeutic impact; enhancing it further may necessitate combination strategies with different therapeutic RNA molecules (siRNA against SOX2 oncogene or other prognosis‐related oncogenes such as HPV oncogenes) within the same tLNPs.